As Chief Financial Officer at Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, Gbola Amusa, MD, MBA, CFA, oversees financial matters and multidisciplinary projects.    

Dr. Amusa previously worked as partner and chief scientific officer at Chardan where he was responsible for advising disruptive health care companies on capital formation strategies, M&A, and other transactions. While in the Chardan equity research department, as partner, disruptive biotech analyst, and/or director of research, Dr. Amusa was focused on identifying companies that will generate exceptionally high long-term investment returns from creating and sharing in real value for society.  Dr. Amusa’s coverage, top picks and counter-consensus calls were associated with exceptional alpha generation, and in a study by TipRanks, Dr. Amusa was ranked second out of more than 6,000 Wall Street analysts for his stock-picking performance. Dr. Amusa was previously managing director, head of European pharma research, and global pharma & biotech coordinator at UBS, where he oversaw 25 analysts and finished as the top ranked European pharma analyst in the Institutional Investor (II) Survey. Prior to UBS, Dr. Amusa was a senior research analyst and head of European pharma research at Sanford C. Bernstein & Co. He started his career in finance at Goldman Sachs as an associate in the healthcare investment banking Group, where he worked on large transactions including the Amgen/Immunex merger. 

Dr. Amusa earned a BSE with honors in biomedical engineering from Duke University, an MD from Washington University Medical School and an MBA (GPA 4.0/4.0) from the University of Chicago, Booth School of Business.